40 citations as recorded by crossref.

1. Prosthetic Knee Infection With Coagulase-Negative Staphylococcus: A Harbinger of Poor Outcomes L. Charalambous et al. https://doi.org/10.1016/j.arth.2022.02.050
2. The Role of Rifampin in Prosthetic Joint Infections: Efficacy, Challenges, and Clinical Evidence J. Pupaibool https://doi.org/10.3390/antibiotics13121223
3. Risk Factors of DAIR Failure and Validation of the KLIC Score: A Multicenter Study of Four Hundred Fifty-Five Patients M. Bernaus et al. https://doi.org/10.1089/sur.2021.320
4. 2025 ICM: Use of Newer Antibiotics and Fluoroquinolone-Resistance F. Sadek et al. https://doi.org/10.1016/j.arth.2025.10.094
5. Efficacy and safety of colistin plus beta-lactams for bone and joint infection caused by fluoroquinolone-resistant gram-negative bacilli: a prospective multicenter study M. Mancheño-Losa et al. https://doi.org/10.1007/s15010-024-02379-7
6. Debridement, antimicrobial therapy, and implant retention (DAIR) as curative strategy for acute periprosthetic hip and knee infections: a position paper of the European Bone & Joint Infection Society (EBJIS) I. Sigmund et al. https://doi.org/10.5194/jbji-10-101-2025
7. Delayed Rifampin Administration in the Antibiotic Treatment of Periprosthetic Joint Infections Significantly Reduces the Emergence of Rifampin Resistance A. Darwich et al. https://doi.org/10.3390/antibiotics10091139
8. Clinical outcome of postoperative surgical site infections in patients with posterior thoracolumbar and lumbar instrumentation T. Zhang et al. https://doi.org/10.1016/j.jhin.2022.06.014
9. Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections D. Tai et al. https://doi.org/10.1093/ofid/ofac363
10. How Often Is Rifampin Therapy Initiated and Completed in Patients With Periprosthetic Joint Infections? D. Kugelman et al. https://doi.org/10.1097/CORR.0000000000003377
11. Incidence of Rifampicin Resistance in Periprosthetic Joint Infection: A Single-Centre Cohort Study on 238 Patients S. Lazarinis et al. https://doi.org/10.3390/antibiotics12101499
12. Material-based treatment strategies against intraosseous implant biofilm infection Z. Pan et al. https://doi.org/10.1016/j.bbrep.2024.101764
13. Review of Recent Advances in Managing Periprosthetic Joint Infection After Total Knee Arthroplasty: DAIR Technique H. Warda et al. https://doi.org/10.2147/ORR.S567611
14. CORR Insights®: Lower Success Rate of Débridement and Implant Retention in Late Acute versus Early Acute Periprosthetic Joint Infection Caused by Staphylococcus spp. Results from a Matched Cohort Study J. Drew https://doi.org/10.1097/CORR.0000000000001283
15. 2025 ICM: Debridement, Antibiotics, and Implant Retention J. Cashman et al. https://doi.org/10.1016/j.arth.2025.10.076
16. Evaluating the Link Between Postoperative Timing of Rifampicin Introduction and the Clinical and Microbiological Outcomes of Orthopedic Staphylococcal Implant Infections V. Dessert et al. https://doi.org/10.3390/antibiotics14101043
17. Rifampin-resistant periprosthetic joint infections are associated with worse functional outcome in both acute and chronic infection types T. Baumgärtner et al. https://doi.org/10.1016/j.diagmicrobio.2024.116447
18. If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study M. Beldman et al. https://doi.org/10.1093/cid/ciab426
19. Rifampin, Rifapentine, and Rifabutin Are Active against Intracellular Periprosthetic Joint Infection-Associated Staphylococcus epidermidis C. Fisher & R. Patel https://doi.org/10.1128/AAC.01275-20
20. Quality of life, infection control, and complication rates using a novel custom-made articulating hip spacer during two-stage revision for periprosthetic joint infection A. Lunz et al. https://doi.org/10.1007/s00402-021-04274-4
21. 2025 ICM: Minimum Biofilm Eradication Concentration (MBEC) Versus Minimum Inhibitory Concentration (MIC) M. Krsak et al. https://doi.org/10.1016/j.arth.2025.10.098
22. Should We Use Rifampicin in Periprosthetic Joint Infections Caused by Staphylococci When the Implant Has Been Exchanged? A Multicenter Observational Cohort Study T. Kramer et al. https://doi.org/10.1093/ofid/ofad491
23. Rifampin in device-related infections: Assessing the modern evidence S. Durham et al. https://doi.org/10.1093/ajhp/zxae263
24. Organism profiles and empirical treatments for periprosthetic joint infections G. Jiang et al. https://doi.org/10.1186/s13018-025-06007-4
25. How We Approach Suppressive Antibiotic Therapy Following Debridement, Antibiotics, and Implant Retention for Prosthetic Joint Infection N. Cortes-Penfield et al. https://doi.org/10.1093/cid/ciad484
26. Bone mineral as a drug-seeking moiety and a waste dump D. Raina et al. https://doi.org/10.1302/2046-3758.910.BJR-2020-0097.R1
27. Clinical outcomes of rifampicin combination therapy in implant-associated infections due to staphylococci and streptococci: A systematic review and meta-analysis E. Yusuf et al. https://doi.org/10.1016/j.ijantimicag.2023.107015
28. Reply to Scheper and de Boer's comment on “Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France” by Becker et al. (2020) A. Becker et al. https://doi.org/10.5194/jbji-6-19-2020
29. Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis H. Scheper et al. https://doi.org/10.1093/ofid/ofab298
30. Extended local release and improved bacterial eradication by adding rifampicin to a biphasic ceramic carrier containing gentamicin or vancomycin S. Sebastian et al. https://doi.org/10.1302/2046-3758.1111.BJR-2022-0101.R1
31. Clinical management of trapeziometacarpal joint infections: a European Delphi consensus and literature review S. Daeschler et al. https://doi.org/10.1177/17531934251385450
32. The Use of Rifampin in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis of Comparative Studies C. Kruse et al. https://doi.org/10.1016/j.arth.2022.03.072
33. In vitroantibiotic activity against intraosteoblasticStaphylococcus aureus: a narrative review of the literature F. Marro et al. https://doi.org/10.1093/jac/dkab301
34. A review of current practices in periprosthetic joint infection debridement and revision arthroplasty H. Mian et al. https://doi.org/10.1186/s42836-022-00136-5
35. Effectiveness and Optimal Duration of Adjunctive Rifampin Treatment in the Management of Staphylococcus aureus Prosthetic Joint Infections After Debridement, Antibiotics, and Implant Retention H. Suzuki et al. https://doi.org/10.1093/ofid/ofac473
36. Rifampicin in periprosthetic joint infections: where do we stand and where are we headed? M. Wouthuyzen-Bakker & H. Scheper https://doi.org/10.1080/14787210.2023.2211263
37. To heal or harm: A systematic review of the role of fluoroquinolones in periprosthetic joint infections S. Tevell et al. https://doi.org/10.1016/j.cmicom.2025.105103
38. Comment on “Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France” by Becker et al. (2020) H. Scheper & M. de Boer https://doi.org/10.5194/jbji-6-17-2020
39. Effectiveness of rifampicin combination therapy for orthopaedic implant-related infections: A systematic review and meta-analysis N. Kobayashi et al. https://doi.org/10.1016/j.ijantimicag.2024.107359
40. Irrigation and Debridement With Chronic Antibiotic Suppression for the Management of Acutely Infected Aseptic Revision Total Joint Arthroplasties H. Salmons et al. https://doi.org/10.1016/j.arth.2023.05.092